Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

Ovarian cancer (OvCa) is a destructive malignancy due to difficulties in early detection and late advanced-stage diagnoses, leading to high morbidity and mortality rates for women. Currently, the quality treatment for OvCa includes tumor debulking surgery and intravenous platinum-based chemotherapy....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Melayshia McFadden, Santosh Kumar Singh, Gabriela Oprea-Ilies, Rajesh Singh
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ovarian cancer nanoparticles targeted drug delivery drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/433a7f45acae4b5a9b21636581610603
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:433a7f45acae4b5a9b21636581610603
record_format	dspace
spelling	oai:doaj.org-article:433a7f45acae4b5a9b216365816106032021-11-11T15:33:39ZNano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers10.3390/cancers132154802072-6694https://doaj.org/article/433a7f45acae4b5a9b216365816106032021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5480https://doaj.org/toc/2072-6694Ovarian cancer (OvCa) is a destructive malignancy due to difficulties in early detection and late advanced-stage diagnoses, leading to high morbidity and mortality rates for women. Currently, the quality treatment for OvCa includes tumor debulking surgery and intravenous platinum-based chemotherapy. However, numerous patients either succumb to the disease or undergo relapse due to drug resistance, such as to platinum drugs. There are several mechanisms that cause cancer cells’ resistance to chemotherapy, such as inactivation of the drug, alteration of the drug targets, enhancement of DNA repair of drug-induced damage, and multidrug resistance (MDR). Some targeted therapies, such as nanoparticles, and some non-targeted therapies, such as natural products, reverse MDR. Nanoparticle targeting can lead to the reversal of MDR by allowing direct access for agents to specific tumor sites. Natural products have many anti-cancer properties that adversely regulate the factors contributing to MDR. The present review displays the current problems in OvCa treatments that lead to resistance and proposes using nanotechnology and natural products to overcome drug resistance.Melayshia McFaddenSantosh Kumar SinghGabriela Oprea-IliesRajesh SinghMDPI AGarticleovarian cancernanoparticlestargeted drug deliverydrug resistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5480, p 5480 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ovarian cancer nanoparticles targeted drug delivery drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ovarian cancer nanoparticles targeted drug delivery drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Melayshia McFadden Santosh Kumar Singh Gabriela Oprea-Ilies Rajesh Singh Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
description	Ovarian cancer (OvCa) is a destructive malignancy due to difficulties in early detection and late advanced-stage diagnoses, leading to high morbidity and mortality rates for women. Currently, the quality treatment for OvCa includes tumor debulking surgery and intravenous platinum-based chemotherapy. However, numerous patients either succumb to the disease or undergo relapse due to drug resistance, such as to platinum drugs. There are several mechanisms that cause cancer cells’ resistance to chemotherapy, such as inactivation of the drug, alteration of the drug targets, enhancement of DNA repair of drug-induced damage, and multidrug resistance (MDR). Some targeted therapies, such as nanoparticles, and some non-targeted therapies, such as natural products, reverse MDR. Nanoparticle targeting can lead to the reversal of MDR by allowing direct access for agents to specific tumor sites. Natural products have many anti-cancer properties that adversely regulate the factors contributing to MDR. The present review displays the current problems in OvCa treatments that lead to resistance and proposes using nanotechnology and natural products to overcome drug resistance.
format	article
author	Melayshia McFadden Santosh Kumar Singh Gabriela Oprea-Ilies Rajesh Singh
author_facet	Melayshia McFadden Santosh Kumar Singh Gabriela Oprea-Ilies Rajesh Singh
author_sort	Melayshia McFadden
title	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_short	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_full	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_fullStr	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_full_unstemmed	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
title_sort	nano-based drug delivery and targeting to overcome drug resistance of ovarian cancers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/433a7f45acae4b5a9b21636581610603
work_keys_str_mv	AT melayshiamcfadden nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers AT santoshkumarsingh nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers AT gabrielaopreailies nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers AT rajeshsingh nanobaseddrugdeliveryandtargetingtoovercomedrugresistanceofovariancancers
_version_	1718435174061965312

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

Ejemplares similares